Clinical features, treatment outcomes and prognostic factors of allopurinol-induced DRESS in 52 patients

被引:6
作者
Liu, Qianling [1 ,2 ]
Zhao, Sumei [2 ]
Chen, Wei [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Minist Hlth & Guangdong Prov,Key Lab Nephrol, Guangzhou, Peoples R China
[2] Capital Med Univ, Beijing Chaoyang Hosp, Dept Nephrol, Beijing, Peoples R China
关键词
allopurinol; drug reaction with eosinophilia and systemic symptoms; drug-induced hypersensitivity syndrome; adverse drug reaction; CUTANEOUS ADVERSE-REACTIONS; SYSTEMIC SYMPTOMS DRESS; HYPERSENSITIVITY SYNDROME; DRUG REACTION; EOSINOPHILIA; GOUT; HYPERURICEMIA; ASSOCIATION; RASH;
D O I
10.1111/jcpt.13667
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is Known and Objective Allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but serious and potentially life-threatening drug hypersensitivity syndrome. In this study, we aimed to investigate the clinical features, treatment outcomes, and prognostic factors of allopurinol-induced DRESS. Methods Case reports of allopurinol-induced DRESS published by China from January 2000 to August 2021 were retrieved from CNKI, Wan Fang, VIP, and PubMed databases for analysis. Results and Discussion This study included 52 patients, consisting of 41 (78.8%) males and 11 (21.2%) females (M:F = 3.7:1). The mean of age was 56.1 +/- 17.1 years (range: 18-86 years). The mean of latency periods was 24.6 +/- 15.0 days (range:1-63 days). Most patients presented with fever, cutaneous eruption, eosinophilia, lymphadenopathy, and facial edema. 36/52 (69.2%) patients showed two or more internal organs involved. Liver and kidney injuries were the most common visceral manifestation. Pulmonary involvement (34.6%), cardiac involvement (25.0%) and gastrointestinal involvement (21.2%) were relatively less known but severe complications. 2/52 (3.8%) patients showed nervous system involved, presenting as leukoencephalopathy or peripheral neuropathy. 2/52 (3.8%) patients presented with secondary hemophagocytic lymphohistiocytosis.1/52 (1.9%) patient developed pure red cell aplasia and 1/52 (1.9%) patient developed painless thyroiditis. HLA*B 58:01 allele was tested in 18/52 (34.6%) patients. 16/18 (88.9%) cases were positive. 48/52 (92.3%) patients were treated with systemic corticosteroids. 16/52 (30.8%) patients were cured, 23/52 (44.2%) patients received partial recovery, and 13/52 (25.0%) patients were died. Septic shock, gastrointestinal bleeding and multiple organ failure were the leading causes of death. Advanced age, underlying cardiovascular disease, chronic kidney disease and high dose of allopurinol, infection and internal organ involvement (including kidney, heart, lung and gastrointestinal tract) were risk factors for death. What is New and Conclusion We explored clinical features, treatment outcomes and prognostic factors of 52 allopurinol-induced DRESS cases in China. Ethnicity, especially Han Chinese, and positive HLA-B*58:01 allele are the clearest risk factors so far. Advanced age, underlying cardiovascular disease, chronic kidney disease and high dose of allopurinol, infection and internal organ involvement (including kidney, heart, lung and gastrointestinal tract) were associated with poorer outcomes. Early identification and discontinuation of the causative drug are crucial to the management of DRESS. For patients with severe disease, corticosteroids are recommended as the first-line therapy. However, further studies are needed to address diagnostic criteria of DRESS for early diagnosis, as well as to develop standardized corticosteroid treatment regimens.
引用
收藏
页码:1368 / 1378
页数:11
相关论文
共 40 条
[11]   2020 American College of Rheumatology Guideline for the Management of Gout [J].
FitzGerald, John D. ;
Dalbeth, Nicola ;
Mikuls, Ted ;
Brignardello-Petersen, Romina ;
Guyatt, Gordon ;
Abeles, A. M. ;
Gelber, Allan C. ;
Harrold, Leslie R. ;
Khanna, Dinesh ;
King, Charles ;
Levy, Gerald ;
Libbey, Caryn ;
Mount, David ;
Pillinger, Michael H. ;
Rosenthal, Ann ;
Singh, Jasvinder A. ;
Sims, James Edward ;
Smith, Benjamin J. ;
Wenger, Neil S. ;
Bae, Sangmee Sharon ;
Danve, Abhijeet ;
Khanna, Puja P. ;
Kim, Seoyoung C. ;
Lenert, Aleksander ;
Poon, Samuel ;
Qasim, Anila ;
Sehra, Shiv T. ;
Sharma, Tarun Sudhir Kumar ;
Toprover, Michael ;
Turgunbaev, Marat ;
Zeng, Linan ;
Zhang, Mary Ann ;
Turner, Amy S. ;
Neogi, Tuhina .
ARTHRITIS & RHEUMATOLOGY, 2020, 72 (06) :879-895
[12]   Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations [J].
Gonzalez-Galarza, Faviel F. ;
Takeshita, Louise Y. C. ;
Santos, Eduardo J. M. ;
Kempson, Felicity ;
Thomaz Maia, Maria Helena ;
Soares da Silva, Andrea Luciana ;
Teles e Silva, Andre Luiz ;
Ghattaoraya, Gurpreet S. ;
Alfirevic, Ana ;
Jones, Andrew R. ;
Middleton, Derek .
NUCLEIC ACIDS RESEARCH, 2015, 43 (D1) :D784-D788
[13]   Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis [J].
Huang, Yu Chen ;
Shih, Po Yu ;
Chin, Szu Ying ;
Chiang, Ying Yi .
JOURNAL OF DERMATOLOGY, 2012, 39 (12) :1077-1078
[14]   DRESS syndrome Part II. Management and therapeutics [J].
Husain, Zain ;
Reddy, Bobby Y. ;
Schwartz, Robert A. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (05) :709.e1-709.e9
[15]  
Isaacs M, 2018, CUTIS, V102, P322
[16]   Less Known Gastrointestinal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of the Literature [J].
Jevtic, Djordje ;
Dumic, Igor ;
Nordin, Terri ;
Singh, Amteshwar ;
Sulovic, Nadezda ;
Radovanovic, Milan ;
Jecmenica, Mladen ;
Milovanovic, Tamara .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
[17]   The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States [J].
Jutkowitz, Eric ;
Dubreuil, Maureen ;
Lu, Na ;
Kuntz, Karen M. ;
Choi, Hyon K. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (05) :594-600
[18]   Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR) [J].
Kano, Yoko ;
Tohyama, Mikiko ;
Aihara, Michiko ;
Matsukura, Setsuko ;
Watanabe, Hideaki ;
Sueki, Hirohiko ;
Iijima, Masafumi ;
Morita, Eishin ;
Niihara, Hiroyuki ;
Asada, Hideo ;
Kabashima, Kenji ;
Azukizawa, Hiroaki ;
Hashizume, Hideo ;
Nagao, Keisuke ;
Takahashi, Hayato ;
Abe, Riichiro ;
Sotozono, Chie ;
Kurosawa, Michiko ;
Aoyama, Yumi ;
Chu, Chia-Yu ;
Chung, Wen-Hung ;
Shiohara, Tetsuo .
JOURNAL OF DERMATOLOGY, 2015, 42 (03) :276-282
[19]   Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study [J].
Kardaun, S. H. ;
Sekula, P. ;
Valeyrie-Allanore, L. ;
Liss, Y. ;
Chu, C. Y. ;
Creamer, D. ;
Sidoroff, A. ;
Naldi, L. ;
Mockenhaupt, M. ;
Roujeau, J. C. .
BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (05) :1071-1080
[20]   Anticonvulsant hypersensitivity syndrome - Incidence, prevention and management [J].
Knowles, SR ;
Shapiro, LE ;
Shear, NH .
DRUG SAFETY, 1999, 21 (06) :489-501